These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 28836572)
41. Impaired Peripheral Endothelial Function Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of In-Stent Restenosis. Komura N; Tsujita K; Yamanaga K; Sakamoto K; Kaikita K; Hokimoto S; Iwashita S; Miyazaki T; Akasaka T; Arima Y; Yamamoto E; Izumiya Y; Yamamuro M; Kojima S; Tayama S; Sugiyama S; Matsui K; Nakamura S; Hibi K; Kimura K; Umemura S; Ogawa H J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27317348 [TBL] [Abstract][Full Text] [Related]
42. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents. Wu XA; Xie G; Li XQ; Wu HT; Wang X Clin Chim Acta; 2018 Apr; 479():20-24. PubMed ID: 29305846 [TBL] [Abstract][Full Text] [Related]
43. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Solinas E; Dangas G; Kirtane AJ; Lansky AJ; Franklin-Bond T; Boland P; Syros G; Kim YH; Gupta A; Mintz G; Fahy M; Collins M; Kodali S; Stone GW; Moses JW; Leon MB; Mehran R Am J Cardiol; 2008 Aug; 102(3):311-5. PubMed ID: 18638592 [TBL] [Abstract][Full Text] [Related]
44. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555 [TBL] [Abstract][Full Text] [Related]
45. Comparison of 2-year outcomes of repeated second-generation drug-eluting stent implantation for focal-type versus nonfocal-type in-stent restenosis. Zhu W; Li J; Luo H; Wang G; Hua Q Coron Artery Dis; 2015 Nov; 26(7):587-91. PubMed ID: 26166020 [TBL] [Abstract][Full Text] [Related]
46. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
47. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry. Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G; EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062 [TBL] [Abstract][Full Text] [Related]
48. [Predictors of in-stent restenosis in coronary heart disease patients complicating with diabetes mellitus within 2 years after drug-eluting stents implantation]. Chen J; Chen Y; Tian F; Han Y; Jing J; Liu J; Wang J; Zhou S Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jan; 42(1):14-8. PubMed ID: 24680263 [TBL] [Abstract][Full Text] [Related]
49. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). Spadaccio C; Patti G; De Marco F; Coccia R; Di Domenico F; Pollari F; Zanzonico R; Pettinari M; Lusini M; Di Sciascio G; Covino E; Chello M Am J Cardiol; 2013 Jul; 112(1):21-6. PubMed ID: 23561587 [TBL] [Abstract][Full Text] [Related]
50. Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year follow-up. Zhao C; Yang L; Mao L; Zhong L; Li X; Wei S Coron Artery Dis; 2013 Aug; 24(5):357-60. PubMed ID: 23835667 [TBL] [Abstract][Full Text] [Related]
51. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508 [TBL] [Abstract][Full Text] [Related]
52. Long-Term Clinical Outcomes after Treatment with Excimer Laser Coronary Atherectomy for In-Stent Restenosis of Drug-Eluting Stent. Ichimoto E; Kadohira T; Nakayama T; De Gregorio J Int Heart J; 2018 Jan; 59(1):14-20. PubMed ID: 29332914 [TBL] [Abstract][Full Text] [Related]
53. Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. Lee JY; Park DW; Kim YH; Yun SC; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ J Am Coll Cardiol; 2011 Mar; 57(12):1349-58. PubMed ID: 21414531 [TBL] [Abstract][Full Text] [Related]
54. Visit-to-visit HbA Yang CD; Shen Y; Lu L; Yang ZK; Hu J; Zhang RY; Shen WF; Ding FH; Wang XQ Cardiovasc Diabetol; 2020 Sep; 19(1):133. PubMed ID: 32887588 [TBL] [Abstract][Full Text] [Related]
55. The impact of main branch restenosis on long term mortality following drug-eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: the Milan and New-Tokyo (MITO) Registry. Takagi K; Ielasi A; Basavarajaiah S; Chieffo A; Shannon J; Godino C; Hasegawa T; Naganuma T; Fujino Y; Latib A; Carlino M; Montorfano M; Nakamura S; Colombo A Catheter Cardiovasc Interv; 2014 Sep; 84(3):341-8. PubMed ID: 24038911 [TBL] [Abstract][Full Text] [Related]
56. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery. Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270 [TBL] [Abstract][Full Text] [Related]
57. Usefulness of Intracoronary Brachytherapy for Patients With Resistant Drug-Eluting Stent Restenosis. Mangione FM; Jatene T; Badr Eslam R; Bergmark BA; Gallagher JR; Shah PB; Mauri L; Leopold JA; Sobieszczyk PS; Faxon DP; Croce KJ; Bhatt DL; Devlin PM Am J Cardiol; 2017 Aug; 120(3):369-373. PubMed ID: 28583681 [TBL] [Abstract][Full Text] [Related]
58. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ J Am Coll Cardiol; 2008 Mar; 51(12):1181-7. PubMed ID: 18355656 [TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty. Oh PC; Suh SY; Kang WC; Lee K; Han SH; Ahn T; Shin EK Korean J Intern Med; 2016 May; 31(3):501-6. PubMed ID: 26951915 [TBL] [Abstract][Full Text] [Related]
60. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]